BioLineRx (BLRX) Free Cash Flow (2013 - 2026)
BioLineRx (BLRX) posted quarterly Free Cash Flow of -$3.2 million for Q4 2025, up 62.86% year-over-year from -$2.0 million in Q4 2024, and down 51.95% quarter-over-quarter from -$2.1 million in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Free Cash Flow (2013 - 2026) Analysis & Trends
BioLineRx's Free Cash Flow history runs 13 years deep, the most recent figure standing at -$3.2 million for Q4 2025.
- In Q4 2025, Free Cash Flow rose 62.86% year-over-year to -$3.2 million; the TTM figure through Dec 2025 stood at -$8.1 million (up 81.57% YoY), while the FY2025 annual figure was -$8.0 million, up 81.63% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$3.2 million, down from -$2.1 million in the prior quarter.
- The five-year high for Free Cash Flow was $5.0 million in Q4 2023, with the low at -$14.1 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$6.2 million (2021), against an average of -$6.2 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 189.0% in 2023, then tumbled 272.08% in 2024.
- BioLineRx's Free Cash Flow stood at -$5.4 million in 2021, then retreated by 3.4% to -$5.6 million in 2022, then jumped by 189.0% to $5.0 million in 2023, then sank by 272.08% to -$8.6 million in 2024, then jumped by 62.86% to -$3.2 million in 2025.
- Business Quant data shows BLRX's Free Cash Flow at -$3.2 million in Q4 2025, -$2.1 million in Q3 2025, and -$177000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -95.09 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 | -3.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -2.27 Mn |
| Dec 31, 2025 | -3.20 Mn |
| Sep 30, 2025 | -2.11 Mn |
| Jun 30, 2025 | -177,000.00 |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | -8.62 Mn |
| Sep 30, 2024 | -9.83 Mn |
| Jun 30, 2024 | -11.30 Mn |
| Mar 31, 2024 | -14.08 Mn |
| Dec 31, 2023 | 5.01 Mn |
| Sep 30, 2023 | -9.90 Mn |
| Jun 30, 2023 | -9.62 Mn |
| Mar 31, 2023 | -7.98 Mn |
| Dec 31, 2022 | -5.79 Mn |
| Sep 30, 2022 | -8.67 Mn |
| Jun 30, 2022 | -6.25 Mn |
| Mar 31, 2022 | -5.57 Mn |
| Dec 31, 2021 | -5.44 Mn |
| Sep 30, 2021 | -5.02 Mn |